Clever Culture Systems Limited · ASX:CC5

Clever Culture Systems — Shareholder Meeting (November 2026)

7 slides from Clever Culture Systems's shareholder meeting presentation, Nov 17, 2026

  1. Slide 1: Managing Director's Presentation – 2026 AGM

    Clever Culture Systems Ltd 16 Anster St Adelaide SA 5000 www.cleverculturesystems.com ASX:CC5 For personal use only MANAGING DIRECTOR’S PRESENTATION – 2026 AGM Adelaide, Australia, 17 November 2026: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) is pleased to provide th

  2. Slide 2: CEO Presentation: AI-powered microbiology

    CEO Presentation AI-powered microbiology personal use only Revolutionising microbial quality control in pharmaceutical manufacturing Annual General Meeting 17 November 2026 Clever Culture Systems ASX: CC5 1

  3. Slide 3: Commercial traction

    Commercial traction H1 FY27 progressing as a step-change in sales performance personal use only COMPLETED H1 FY 2 7 S A LE S A ND N EW EV A L UA TI ON S 3 Sales completed and invoiced in Q1 FY27 to Novo and AstraZeneca APAS® instruments 2 Purchase orders received from existing global pharma customer

  4. Slide 4: APAS Revolution: Substantial growth opportunity unlocked

    APAS® Revolution Substantial growth opportunity unlocked personal use only Built on proven APAS® technology, funded and launching H1 CY2028 $4.3B ~50% 3,400 <2 yrs revised increased TAM uplift to APAS® TAM instrument opportunity payback after launch TIMELINE Nov 2026 Next CY2027 CY2028 Within 2 year

  5. Slide 5: Expanded opportunity

    Expanded opportunity Targeting a 5,700 APAS® instrument TAM: $4.3B personal use only APAS® platforms to address the entire market opportunity APAS® Revolution APAS® Independence 3,400 instrument opportunity / $1.5B 2,300 instrument opportunity / $2.8B 30% 25% 20% 15% 10% 5% 25% 25% 25% 15% 10% 0% <1

  6. Slide 6: Same revenue model

    Same revenue model One revenue model across both APAS instruments personal use only Independence and Revolution share a broadly equivalent revenue split1 Product / Approx. Description Revenue Model Service Split APAS® Upfront Capex APAS® Independence (inc. financing 40% Instruments and APAS® Revoluti

  7. Slide 7: Growth outlook

    Growth outlook TODAY NEXT personal use only Today: APAS® proven and Scale: building on that building trust with global success to increase global pharma market opportunity 37 instruments 9 top-20 pharma GMP use routinely Second product, Recurring revenue Broad based installed customers by customers

Clever Culture Systems — Shareholder Meeting (November 2026) on 6ix